Literature DB >> 2413302

Sustained protection by iloprost of the porcine heart in the acute and chronic phases of myocardial infarction.

C D de Langen, W H van Gilst, H Wesseling.   

Abstract

The effects of iloprost (ZK 36 374) on myocardial ischemia and infarction were studied in three groups of four anesthetized and heparinized pigs. Coronary microembolization was evoked by the injection of microspheres (50 microM) into the left coronary artery. A dose of 12 million beads/kg was followed by ventricular fibrillation and death after 11 +/- 5 min (group A). In group B, ischemia was evident at 15 min after the injection of 6 million beads/kg from an ST segment elevation in the precordial electrocardiogram (2.9 +/- 1.1 mV; p less than 0.05) and from an arterial-coronary venous difference in inosine concentration of -8.5 +/- 0.3 microM (p less than 0.05). However, in the presence of iloprost--an infusion of 0.18 micrograms/kg/min started 30 min before embolization--no ST segment elevation (0.45 +/- 0.23 mV; NS) or inosine release (-1.5 +/- 1.0 microM) was detected after the injection of 12 million beads/kg (group C). After 7 days, the animals from group B had more frequent spontaneous ventricular arrhythmias than those from group C. Programmed electrical stimulation induced intraventricular reentry in some animals of both groups (3 of 4 in B and 2 of 4 in C). Ventricular tachycardia was induced in two animals from group B. Postmortem examination revealed small myocardial infarcts in all group B animals; however, in group C no infarcts were detected. These data corroborate the view that prostacyclin-mimetic compounds are beneficial in the acute and in the chronic phases of myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413302     DOI: 10.1097/00005344-198509000-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig.

Authors:  R A Tio; C D de Langen; P A de Graeff; W H van Gilst; K J Bel; K G Wolters; P H Mook; J van Wijngaarden; H Wesseling
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

2.  Beneficial effect of beraprost, a prostacyclin-mimetic agent, on post-hypoxic recovery of cardiac function and metabolism in rabbit isolated hearts.

Authors:  K Tanonaka; Y Maruyama; S Takeo
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

3.  Prostacyclin and iloprost: equal efficiency in preserving high energy phosphates in the dog heart following coronary artery ligation.

Authors:  M Pissarek; H Goos; J Nöhring; J Graff; G Buller; I Beyerdörfer; H J Mest; K F Lindenau; E G Krause
Journal:  Basic Res Cardiol       Date:  1987 Nov-Dec       Impact factor: 17.165

4.  Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts.

Authors:  R Ferrari; A Cargnoni; S Curello; G M Boffa; C Ceconi
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

5.  Effects of iloprost, a PGI2 derivative, on ischemic myocardial energy and carbohydrate metabolism in dogs.

Authors:  K Ichihara; K Yamamoto; Y Abiko
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396

Review 6.  Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Authors:  S M Grant; K L Goa
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.